别嘌醇联合非布司他治疗痛风急性关节炎患者的临床疗效分析

Clinical Efficacy Analysis of Allopurinol Combined with Febuxostat in the Treatment of Patients with Acute Arthritis of Gout

目的分析别嘌醇联合非布司他治疗痛风急性关节炎患者的临床疗效。方法本研究选取2021年5月—2023年5月山东省阳信县人民医院收治的62例痛风急性关节炎患者为研究对象,并将其分为治疗组和对照组,每组31例。对照组采用别嘌醇治疗,治疗组采用别嘌醇与非布司他联合治疗,两组均治疗1周。比较两组疼痛视觉模拟评分(VAS)、红细胞沉降率(ESR)、C反应蛋白(CRP)及血尿酸(UA)水平。结果治疗组临床总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组VAS评分比较,差异无统计学意义(P>0.05)。治疗后,两组VAS评分均较治疗前降低,且治疗组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组ESR、CRP水平比较,组间差异无统计学意义(P>0.05)。治疗后,两组ESR、CRP水平均较治疗前降低,且治疗组均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组UA水平比较,差异无统计学意义(P>0.05)。治疗1周后,两组UA水平均较治疗前降低,且治疗组低于对照组,但差异无统计学意义(P>0.05);治疗1个月后,两组UA水平均较治疗前降低,且治疗组低于对照组,差异有统计学意义(P<0.05)。结论别嘌醇联合非布司他治疗痛风急性关节炎患者比单一使用别嘌醇更有效,这种联合治疗策略不仅能更有效地缓解关节疼痛,还能更好地控制血尿酸水平,为痛风急性关节炎的治疗提供了新的视角。

Objective To analyze the clinical efficacy of allopurinol combined with febuxostat in the treatment of acute arthritis of gout.Methods 62 patients with acute arthritis of grout treated in Yangxin County People's Hospital of Shandong Province from May 2021 to May 2023 were selected as the research objects and divided into a treatment group and a control group,with 31 cases in each group.The control group was treated with allopurinol,and the treatment group was treated with allopurinol and febuxostat.Both groups were treated for 1 week.Pain Visual Analogue Scale(VAS),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)and blood uric acid(UA)levels were compared between the two groups.Results The total clinical effective rate of the treatment group was higher than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in VAS scores between the two groups(P>0.05).After treatment,VAS scores in both groups were lower than before treatment,and the treatment group was lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in ESR and CRP levels between the two groups(P>0.05).After treatment,the levels of ESR and CRP in both groups were lower than before treatment,and the treatment group was lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in UA levels between the two groups(P>0.05).After 1 week of treatment,the UA level in both groups was lower than before treatment,and the treatment group was lower than the control group,but the differences were not statistically significant(P>0.05).After 1 month of treatment,the UA level in both groups was lower than before treatment,and the treatment group was lower than the control group,the differences were statistically significant(P<0.05).Conclusion Allopurinol combined with febuxoat is more effective than allopurinol alone in the treatment of acute arthritis of gout.This combined treatment strategy can not only relieve joint pain more effectively,but also better control blood uric acid level,providing a new perspective for the treatment of acute arthritis of gout.